Pharmafile Logo

Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

December 11, 2025 | Pharmaphorum 

Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

- PMLiVE

We’re pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum’s latest “12 Questions” interview series.

In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models.

Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey.

Read the full interview on pharmaphorum.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...